Stent Clinical Trial Taxus® and Cypher® in Diabetics

by Editor on October 23, 2006 in Asides

While re-intervention rates at one year were similar between arch rivals Johnson and Johnson and Boston Scientific, this study claims that Taxus® has statistically superior performance in the fast growing diabetic population.

Boston Scientific Corporation – TAXUS® Performance Superior to Cypher® in Diabetic Patients in Head-to-Head Study

Bookmark and Share

Related posts:

  1. J&J Cypher Stent Sort Out III Study VS Medtronic Endeavor Stent
  2. FDA Statement on Coronary Drug-Eluting Stents
  3. J&J – Conor CoStar(r) Clinical Trial Stent Stopped
  4. Do drug eluting stents DES increase deaths?
  5. Clinical Trials – Diabetes Heart Risk Reduced

Tags:

Post Author

This post was written by Editor who has written 96 posts on the international medical market place.

No comments yet.

Leave a Reply